UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association between FAS polymorphism and prostate cancer development

Prostate cancer and prostatic diseases, 2008-03, Vol.11 (1), p.94-98

2008

Volltextzugriff (PDF)

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

The pharmacogenomics journal, 2009-10, Vol.9 (5), p.341-346

2009

Volltextzugriff (PDF)

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration

European journal of cancer (1990), 2014-01, Vol.50 (2), p.359-365

2014

Volltextzugriff (PDF)

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14623-14623

2006

Volltextzugriff (PDF)

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15579-15579

2007

Volltextzugriff (PDF)

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4777-4777

2005

Volltextzugriff (PDF)

Fas-670 polymorphism and prostate cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21028-21028

2007

Volltextzugriff (PDF)

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5125-5125

2007

Volltextzugriff (PDF)

563 Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e563-e563

2015

Volltextzugriff (PDF)

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16034-16034

2008

Volltextzugriff (PDF)

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5064-5064

2008

Volltextzugriff (PDF)

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Annals of oncology, 2009-07, Vol.20 (7), p.1264-1269

2009

Volltextzugriff (PDF)

Phase III intermittent MAB vs continuous MAB

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4513-4513

2006

Volltextzugriff (PDF)

Relative importance of sexuality and quality of life in patients with prostatic symptoms : Results of an international study

European urology, 1997, Vol.31 (3), p.272-280

1997

Volltextzugriff (PDF)

Intermittent hormone therapy: Not a standard for many urologists and oncologists. Why?

European urology supplements : official journal of the European Association of Urology, 2016, Vol.15 (2), p.62-62a

Calais Da Silva, F

2016

Volltextzugriff (PDF)

380 Combined analysis of SNPs in IL-6/IL-6R pathway predict prostate cancer aggressiveness and development of resistance to hormonal castration

European journal of cancer supplements, 2010, Vol.8 (5), p.97-97

2010

Volltextzugriff (PDF)

97 Non-synonym leptin receptor genetic variants, prostate cancer susceptibility and aggressiveness

European journal of cancer supplements, 2010, Vol.8 (5), p.25-26

2010

Volltextzugriff (PDF)

96 Adiponectin functional polymorphisms and haplotype are associated with prostate cancer aggressiveness and to hormonal castration resistance

European journal of cancer supplements, 2010, Vol.8 (5), p.25-25

2010

Volltextzugriff (PDF)

89 Influence of functional genetic variants of TGFβ1/TGFβR2 pathway in prostate cancer development

European journal of cancer supplements, 2010, Vol.8 (5), p.23-24

2010

Volltextzugriff (PDF)

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

Cancer, 1990-09, Vol.66 (5), p.1009-1016

1990

Volltextzugriff (PDF)

1101 Prostate cancer and apoptosis: An insight of FAS-670A/G polymorphism role in tumor development

European journal of cancer supplements, 2009, Vol.7 (2), p.115-115

2009

Volltextzugriff (PDF)

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

The Journal of urology, 2001-08, Vol.166 (2), p.476-481

2001

Volltextzugriff (PDF)

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Oncology, 2003-01, Vol.65 Suppl 1, p.24-28

2003

Volltextzugriff (PDF)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008-05, Vol.53 (5), p.941-949

2008

Volltextzugriff (PDF)

7023 Osteopontin functional genetic polymorphism is associated with prostate cancer biochemical recurrence and androgen independence

European journal of cancer supplements, 2009, Vol.7 (2), p.413-413

2009

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(104)
Tagungsberichte
(1)

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

Humans
(31)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Male
(28)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Aged
(17)
Middle Aged
(17)
Urology
(17)
Urology & Nephrology
(17)
Hematology, Oncology And Palliative Medicine
(14)
Pharmacology. Drug Treatments
(13)
Quality Of Life
(11)
Chemotherapy
(10)
Nephrology. Urinary Tract Diseases
(10)
Oncology
(10)
Prostatic Neoplasms - Pathology
(10)
Tumors Of The Urinary System
(10)
Urinary Tract. Prostate Gland
(10)
Aged, 80 And Over
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association between FAS polymorphism and prostate cancer development

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Fas-670 polymorphism and prostate cancer

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

563 Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Phase III intermittent MAB vs continuous MAB

Relative importance of sexuality and quality of life in patients with prostatic symptoms : Results of an international study

Intermittent hormone therapy: Not a standard for many urologists and oncologists. Why?

380 Combined analysis of SNPs in IL-6/IL-6R pathway predict prostate cancer aggressiveness and development of resistance to hormonal castration

97 Non-synonym leptin receptor genetic variants, prostate cancer susceptibility and aggressiveness

96 Adiponectin functional polymorphisms and haplotype are associated with prostate cancer aggressiveness and to hormonal castration resistance

89 Influence of functional genetic variants of TGFβ1/TGFβR2 pathway in prostate cancer development

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

1101 Prostate cancer and apoptosis: An insight of FAS-670A/G polymorphism role in tumor development

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

7023 Osteopontin functional genetic polymorphism is associated with prostate cancer biochemical recurrence and androgen independence

Suchergebnisse filtern